BEDMINSTER, N.J., Nov. 24, 2020 /PRNewswire/ -- Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that an abstract related to its dual LSD1 and HDAC6 inhibitor, JBI-802, has been accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting taking place Dec. 5-8, 2020.
"We look forward to discussing our novel potent and selective dual inhibitor of LSD1-HDAC6 for the treatment of cancer at the 2020 ASH Virtual Annual Meeting," said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics. "Our work to progress JBI-802 into the clinic as a potential, differentiated therapeutic for the treatment of select hematological and solid tumors with specific gene signatures is on track and we expect to initiate first-in-human studies in the second half of next year."
The abstract, currently available on the ASH conference website, is as follows:
Title: Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer
Date:Monday, December 7, 2020
Session: 802. Chemical Biology and Experimental Therapeutics: Poster III
Presenter: Dhanalakshmi Sivanandhan, Ph.D., Associate Vice President & Head of Biology, Jubilant Therapeutics Inc.
About Jubilant Therapeutics
Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations. The Company's entrepreneurial-minded leadership and scientific teams strive for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences Limited's value chain and shared services. Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members. For more information, please visit www.jubilanttx.com or follow us on Twitter @JubilantTx and LinkedIn.
SOURCE Jubilant Therapeutics Inc.
To read more Press Release articles, click here.